HALO logo
halo search icon
Relay Therapeutics, Inc.

US$13.02

Price Change Indicator
0.95 (7.87%)
Relay Therapeutics, Inc.
RLAY · NAS

Relay Therapeutics, Inc.

Start Trading RLAY for Free

US$13.02

Price Arrow0.95 (7.87%)
20/05/2026 04:00:00 PM
All-CompaniesAll-ConsensusBig Candle (Realtime)Engulfing BullishEngulfing Bullish (Realtime)HALO AllHALO MomentumRecent Price upgrade
Consensus Score
Lock Icon/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

Relay Therapeutics, Inc. Overview

RLAY Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

HALO Model

Mqv

Very Weak

Garp

Very Weak

Mqv Small

Neutral

Valuation

Value

Lock Icon

Consensus

Lock Icon

Momentum

Price

Weak

Earnings

Strong

Growth

Earnings

Weak

Dividends

Very Weak

Quality

Capital Efficiency

Very Weak

Balance Sheet

Very Weak

About RLAY

icon
icon

Telephone

1.617.370.8837

icon

Address

60 Hampshire Street, Cambridge, MA 02139

Description

Relay Therapeutics, Inc. engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. Its Dynamo platform is use to integrate an array of edge experimental and computational approaches, which allows to apply the understanding of protein structure and motion to drug discovery. The company was founded by David Elliot Shaw, Matthew P. Jacobson, Dorothee Kern, Mark Murcko, Alexis Borisy, and Jakob Loven on May 4, 2015 and is headquartered in Cambridge, MA.

RLAY Price Chart

Key Stats

Market Cap

US$2.31B

PE

0.00

EV/EBITDA

N/A

Dividends Overview

DIV Yield

0%

Franking

0%

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 2.75 - 17.32

Trade Value (12mth)

US$4,703,087.00

1 week

-1.07%

1 month

-28.15%

YTD

47.56%

1 year

322.03%

All time high

64.37

Key Fundamentals

EPS 3 yr Growth

-37.70%

EBITDA Margin

NaN%

Operating Cashflow

-$235m

Free Cash Flow Return

-33.20%

ROIC

-39.00%

Interest Coverage

0.00

Quick Ratio

22.60

Other Data

Shares Outstanding (Fully Diluted)

180m

HALO Sector

Healthcare

Next Company Report Date

25-Feb-27

Next Ex Dividend Date

N/A

Next Dividend Pay Date

N/A

Reporting Currency

USD

Short Sell (% of issue)

0.00

RLAY Announcements

Latest Announcements

DateAnnouncements
20 May 26
19 May 26
19 May 26
19 May 26
06 May 26

RLAY Fundamentals

Per Share Records

Historical data

Forecast data

USD2021202220232024202320242025202620272028
Per Share, Growth & Valuations
EPS (Basic)
 $locklocklocklock-2.79-2.36-1.61locklocklock
EPS (Fully Diluted)
 $locklocklocklock-2.79-2.36-1.61locklocklock
Growth
 %locklocklocklock-7.815.331.8locklocklock
PE
 XlocklocklocklockN/AN/AN/Alocklocklock
EV/EBITDA
 XlocklocklocklockN/AN/AN/Alocklocklock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

0%

Franking Level

0%

DPSg

N/A

Quality Yield

lock

Falling Divs over next 2

lock

Want to learn more?Frequently asked questions.
What is the current share price of Relay Therapeutics, Inc. (RLAY:NAS)?
Halo FAQ
The current share price of Relay Therapeutics, Inc. (RLAY:NAS) is USD$13.02.
What is the 52-week high share price for Relay Therapeutics, Inc. (RLAY:NAS)?
Halo FAQ
The 52-week high share price for Relay Therapeutics, Inc. (RLAY:NAS) is USD$17.32.
What is the 52-week low share price for Relay Therapeutics, Inc. (RLAY:NAS)?
Halo FAQ
The 52-week low share price for Relay Therapeutics, Inc. (RLAY:NAS) is USD$2.75.
What is the dividend yield for Relay Therapeutics, Inc. (RLAY:NAS)?
Halo FAQ
Relay Therapeutics, Inc. (RLAY:NAS) does not pay a dividend.
What was Relay Therapeutics, Inc. (RLAY:NAS) last dividend payment?
Halo FAQ
Relay Therapeutics, Inc. (RLAY:NAS) does not pay a dividend.
What is the franking level for Relay Therapeutics, Inc. (RLAY:NAS)?
Halo FAQ
Relay Therapeutics, Inc. (RLAY:NAS) has a franking level of 0.00%.
In which sector is Relay Therapeutics, Inc. (RLAY:NAS) classified?
Halo FAQ
Relay Therapeutics, Inc. (RLAY:NAS) is classified in the Healthcare.

See beyond the curve.

One solution for research, investing and portfolio management.
Start FREE Trial